Omeprazole (A2845) in Gastric Acid Secretion Research: Technical Best Practices

What This Product Solves

Omeprazole (SKU A2845), chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a potent H+,K+-ATPase inhibitor designed for research applications that require precise modulation of gastric acid secretion. With an IC50 of 5.8 μM for H+,K+-ATPase inhibition and 0.16 μM for histamine-induced acid formation, this compound is a standard tool for antiulcer activity studies and peptic ulcer disease models. Its high purity (∼98%) and specificity make it particularly suitable for experiments evaluating mechanisms of gastric acid-related disorders, as well as for antiulcer agent screening workflows (product_spec).

For an expanded discussion of the compound's versatility in peptic ulcer disease models and its role as a gold-standard H+,K+-ATPase inhibitor, see the internal article here. Additionally, translational guidance on leveraging this molecule in advanced gastric acid secretion and gut–liver–brain axis research is available here.

Protocol Parameters

• H+,K+-ATPase activity assay | IC50 = 5.8 μM | Quantitative inhibition of H+,K+-ATPase in vitro | Establishes working concentrations for enzyme inhibition studies | product_spec
• Gastric acid formation (histamine-induced) | IC50 = 0.16 μM | Models requiring suppression of stimulated gastric acid secretion | Optimizes dose range for antiulcer activity study | product_spec
• Compound solubility in DMSO | ≥17.27 mg/mL | Stock solution preparation for cell-based or ex vivo assays | Ensures adequate dissolution in experimental protocols | product_spec
• Solid storage temperature | -20°C | Long-term maintenance of chemical integrity | Prevents degradation and maintains batch quality | product_spec
• Solution storage recommendation | Short-term only; avoid long-term storage | Immediate use in workflow | Solution stability is limited; prepare fresh for each experiment | workflow_recommendation

Workflow Setup and QC Checklist

• Compound Handling: Omeprazole is insoluble in water and ethanol; dissolve only in DMSO to prepare concentrated stock solutions. Use a fume hood and wear appropriate PPE.
• Stock Preparation: Prepare stock solutions at concentrations up to 17.27 mg/mL in DMSO. Vortex thoroughly to ensure complete dissolution.
• Aliquoting and Storage: Store solid powder at -20°C in a desiccated, tightly sealed container. Avoid repeated freeze-thaw cycles. Aliquot DMSO stocks for single-use to minimize degradation. Do not store solutions for extended periods; prepare fresh aliquots for each experiment (product_spec).
• Quality Control: Confirm lot-specific purity (∼98%) prior to use. Document lot number, preparation date, and storage conditions in your laboratory notebook.
• Shipping Verification: Ensure shipment arrives on blue ice and is promptly transferred to appropriate storage upon receipt.

Common Failure Modes and Fixes

• Incomplete Dissolution: If undissolved material is observed in DMSO, increase vortexing time or gently warm the solution (avoid excessive heat). Do not attempt dissolution in water or ethanol, as the compound is insoluble in these solvents (product_spec).
• Solution Degradation: Decreased activity or color change in DMSO stocks may indicate degradation. Prepare fresh solutions for each use and discard old aliquots.
• Reduced Inhibitory Activity: Confirm IC50-based dosing with control experiments if inhibition is suboptimal. Verify that the stock solution was freshly prepared and not stored beyond recommended timeframes.
• Batch Purity Concerns: Utilize only lots verified at ∼98% purity. If lower purity is detected, adjust calculations and consider additional controls.

Scope and Limitations

• Intended Use: This product is strictly for scientific research. It is not for diagnostic or clinical applications (product_spec).
• Compound Stability: Omeprazole is stable as a solid at -20°C; however, its solution form is prone to degradation. Do not rely on long-term storage of working solutions.
• Experimental Compatibility: Designed for studies involving H+,K+-ATPase inhibition, gastric acid secretion research, and peptic ulcer disease models. Not validated for off-target or in vivo translational studies unless supported by additional evidence.
• Solvent Restrictions: Use exclusively with DMSO as the solvent for stock preparations. Avoid aqueous or alcoholic solvents to prevent precipitation and loss of activity.

Conclusion

For researchers investigating gastric acid-related disorders, the high-purity H+,K+-ATPase inhibitor Omeprazole (A2845) offers a robust, well-characterized option for in vitro and ex vivo workflows. Adherence to precise solubility, storage, and dosing guidelines is essential for replicable results and optimal compound performance. For further details, refer to the APExBIO product page and related technical resources.